Palvella Therapeutics (PVLA) Other Working Capital Changes (2014 - 2024)

Palvella Therapeutics (PVLA) has reported Other Working Capital Changes for 13 consecutive years, with $357000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Working Capital Changes rose 143.59% year-over-year to $357000.0; the TTM figure through Mar 2026 stood at -$188000.0 (down 125.47% YoY), while the FY2025 annual figure was -$1.4 million, down 190.75% from the prior year.
• Other Working Capital Changes held at -$49000.0 in Q1 2026 per PVLA's latest filing.
• Across five years, Other Working Capital Changes topped out at $19.7 million in Q1 2022 and bottomed at -$47.6 million in Q4 2022.
• Historically, Other Working Capital Changes has averaged -$1.2 million across 5 years, with a median of $134000.0 in 2024.
• Annual changes were most pronounced in 2023 — Other Working Capital Changes surged 3341.02% — and 2025, when it sank 1416.67%.
• Palvella Therapeutics' Other Working Capital Changes stood at -$47.6 million in 2022, then rose by 28.37% to -$34.1 million in 2023, then soared by 103.7% to $1.3 million in 2024, then plunged by 117.62% to -$222000.0 in 2025, then soared by 260.81% to $357000.0 in 2026.
• Business Quant data shows PVLA's Other Working Capital Changes at $357000.0 in Q1 2026, -$222000.0 in Q4 2025, and -$182000.0 in Q3 2025.